Skip to main content
 

Past and future therapy for hepatitis C

Wednesday, November 12, 2014

Speaker

Jay H. Hoofnagle, M.D.
Deputy Director, Division of Digestive Diseases and Nutrition and Deputy Director, Liver Disease Branch
NIDDK/NIH

Dr. Hoofnagle has studied Hepatitis C, the most critical area of all liver disease research, for over 30 years. Dr. Hoofnagle will discuss the hepatitis C virus, new insights in how it harms the liver, and new developments of new direct acting antivirals that now promise to cure the majority of patients with this very important liver disease.

Summary

The Astute Clinician series honors a U.S. clinician-scientist who has observed an unusual clinical occurrence, and by investigating it, has opened an important new avenue of research. Dr. Jay H. Hoofnagle, an expert in liver diseases, has been involved in early evaluation and development of virtually all antiviral agents developed for viral hepatitis including interferon, ribavirin, lamivudine and adefovir dipivoxil.


The page was last updated on Tuesday, April 28, 2015 - 8:49pm